Tesamorelin + Ipamorelin (Blend)

Tesamorelin and Ipamorelin are two peptides that stimulate growth hormone release through separate pathways—Tesamorelin via the GHRH receptor and Ipamorelin via the ghrelin receptor—with research exploring their complementary effects on GH output.
Disclaimer: Tesamorelin and Ipamorelin are not approved for combined therapeutic use and are classified as research peptides. This content is intended for educational and informational purposes only.

What is Tesamorelin + Ipamorelin (Blend)?

Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone (GH) through the natural GHRH pathway. It has a 44–amino acid structure with modifications that increase its stability and half-life compared to natural GHRH. Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist that triggers GH release via a separate pathway from GHRH. When used together in research settings, Tesamorelin and Ipamorelin may have complementary effects on GH release by acting on two different hormonal signaling mechanisms.



Mechanisms of Action

Tesamorelin + Ipamorelin may work together by:

  • Tesamorelin: Binding to GHRH receptors in the pituitary to increase GH pulse amplitude and frequency
  • Ipamorelin: Activating ghrelin receptors (GHS-R1a) to enhance GH secretion without significantly affecting cortisol or prolactin levels
  • Potentially increasing circulating insulin-like growth factor-1 (IGF-1) to support tissue growth and repair
  • Acting synergistically to promote a greater and more sustained GH release than either peptide alone
  • Supporting protein synthesis, tissue recovery, and metabolic regulation in research models
This blend contains

Research Highlights

Research on

Tesamorelin

FDA-Approved for HIV-Associated Visceral Fat Reduction

Tesamorelin (Egrifta®) is FDA-approved for reducing visceral adipose tissue (VAT) in patients with HIV-associated lipodystrophy, with clinical trials demonstrating significant VAT loss and improvements in body composition, lipid profile, and insulin sensitivity.

Source: Metical Anti-Aging Evidence

Versatile Metabolic & Longevity Applications

Emerging research is exploring Tesamorelin’s effects beyond HIV lipodystrophy, including reducing hepatic steatosis and liver fibrosis in NAFLD, improving cognitive function, insulin resistance, and other aging-related metabolic markers.

Source: PeptidesWiki Clinical Trial Summary

Ongoing Research in Cognitive Aging & Nerve Repair

Current Phase II trials are evaluating Tesamorelin’s potential in improving cognitive function in aging HIV populations, and in enhancing motor and sensory recovery after peripheral nerve injuries.

Source: CenterWatch Clinical Trial Listing

Favorable Metabolic Biomarker Profiles

Tesamorelin has been shown to improve lipid metabolism—lowering triglycerides by ~15% and increasing HDL—while maintaining or even enhancing insulin sensitivity, and improving glucose homeostasis.

Source: Biology Insights Metabolic Overview
Research on

Ipamorelin

Selective GH Secretagogue (GHS‑R1a Agonist)

Ipamorelin binds specifically to the ghrelin receptors in the pituitary, inducing growth hormone (GH) release without significantly impacting cortisol, ACTH, or prolactin—offering a cleaner profile compared to other GHRPs.

Source: pep-pedia

Musculoskeletal Support & Bone Health

Animal studies indicate that Ipamorelin may counteract glucocorticoid-induced muscle catabolism and increase bone mineral content, particularly enhancing tibial growth and bone density in female rats.

Source: sagepub

Precise, Pulsatile GH Release

Ipamorelin closely mimics natural GH secretion patterns by delivering targeted pulses, which helps maintain physiological hormone balance and potentially improves metabolic responses.

Source: propeptidesource

Potential Anti-Aging & Recovery Applications

Due to its selectivity and minimal hormonal side effects, Ipamorelin is under investigation as a research tool for muscle recovery, anti-aging protocols, and metabolic studies.

Source: regentherapy

Molecular Structure

Tesamorelin

Sequence

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-NH₂

Molecular Formula

C₂₂₀H₃₆₆N₇₂O₆₇S

Molecular Weight

5135.91 g/mol

Source
PubChem

Ipamorelin

Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (Aib = 2-aminoisobutyric acid, 2-Nal = 2-naphthylalanine)

Molecular Formula

C₃₈H₄₉N₉O₅

Molecular Weight

711.86 g/mol

Source
PubChem

Sources